Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Procter & Gamble Health's EBIT per Share for the
three
months ended in Jun. 2026 was ₹77.87.
Its EBIT per Share for the trailing twelve months (TTM) ended in Jun. 2026 was ₹295.90.
During the past 12 months, the average EBIT per Share Growth Rate of Procter & Gamble Health was 14.40% per year.
During the past 3 years, the average EBIT per Share Growth Rate was 20.50% per year.
During the past 5 years, the average EBIT per Share Growth Rate was 15.50% per year.
During the past 10 years, the average EBIT per Share Growth Rate was 19.50% per year.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the EBIT per Share growth rate using EBIT per Share data.
The historical rank and industry rank for Procter & Gamble Health's EBIT per Share or its related term are showing as below:
BOM:500126'
s 3-Year EBIT Growth Rate Range Over the Past 10 Years
Min: -19.5 Med: 8.8 Max: 40.6
Current: 20.5
During the past 13 years, the highest 3-Year average EBIT per Share Growth Rate of Procter & Gamble Health was 40.60% per year. The lowest was -19.50% per year. And the median was 8.80% per year.
BOM:500126's 3-Year EBIT Growth Rate is ranked worse than 50.25% of 812
companies
in the Drug Manufacturers industry
Industry Median: 7.5
vs BOM:500126: 20.50
Procter & Gamble Health (BOM:500126) EBIT per Share Explanation
EBIT is a company's earnings before interest and tax expenses are deducted. It measures a company's profit generates from operating, ignoring tax burden and capital structure. As the tax expense are not deducted, EBIT is helpful when comparing companies in the same industry but with different tax situations. Also, the interest expense are included in EBIT, making it useful to compare companies that have high interest expenses due to large amount of debt.
Procter & Gamble Health EBIT per Share Related Terms
Procter & Gamble Health EBIT per Share Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
EBIT per Share for the trailing twelve months (TTM) ended in Jun. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was ₹295.90
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Procter & Gamble Health (BOM:500126) has a EBIT per Share of ₹295.90 as of Jun. 2026. EBIT per Share is the amount of Earnings Before Interest and Taxes per outstanding share of the company's stock. View historical data on Procter & Gamble Health and its competitors. According to the industry distribution chart, Procter & Gamble Health ranks #408 out of 812 companies in the Drug Manufacturers industry, placing it in the top 50.2%.
Is Procter & Gamble Health's EBIT per Share too high?
Procter & Gamble Health's current EBIT per Share is ₹295.90. Based on the distribution chart, Procter & Gamble Health ranks #408 out of 812 companies in the Drug Manufacturers industry, which is below the industry midpoint. Overall, Procter & Gamble Health has a GF Score™ of 76/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Procter & Gamble Health's EBIT per Share compare to ZTS?
According to the Drug Manufacturers industry distribution chart, Procter & Gamble Health ranks #408 out of 812 companies for EBIT per Share. This places Procter & Gamble Health in the lower half of its industry. The industry median EBIT per Share is 7.50. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBIT per Share for a Drug Manufacturers company?
The median EBIT per Share among Drug Manufacturers companies is 7.50, based on 812 companies in the industry. Companies in the top quartile (top 25%) have a EBIT per Share significantly above this median, while those in the bottom quartile fall well below. However, EBIT per Share should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBIT per Share mean?
A high EBIT per Share can signal that a stock is expensive relative to its fundamentals. EBIT per Share is the amount of Earnings Before Interest and Taxes per outstanding share of the company's stock. View historical data on Procter & Gamble Health and its competitors. For the Drug Manufacturers industry, the median EBIT per Share is 7.50 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Procter & Gamble Health's current EBIT per Share is ₹295.90. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Procter & Gamble Health stock overvalued right now?
Based on GuruFocus' analysis, Procter & Gamble Health (BOM:500126) is currently considered Fairly Valued. The stock's GF Value™ is ₹6,401.51, compared to a current price of ₹6,030.35 — trading 5.8% below its estimated fair value. The current EBIT per Share is ₹295.90. Procter & Gamble Health's overall GF Score™ is 76/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBIT per Share calculated?
EBIT per Share is calculated from a company's financial statements. For Procter & Gamble Health (BOM:500126), the current EBIT per Share is ₹295.90 as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Procter & Gamble Health (BOM:500126) Overvalued in 2026?
Based on GuruFocus' analysis, Procter & Gamble Health stock appears to be undervalued.
The current stock price of ₹6,030.35 is trading 5.8% below its estimated GF Value™ of ₹6,401.51.
GuruFocus considers Procter & Gamble Health to be Fairly Valued.
Key valuation signals for BOM:500126:
EBIT per Share: ₹295.90
GF Value™: ₹6,401.51 vs. price of ₹6,030.35 (5.8% below fair value)
No single metric tells the full story. See the BOM:500126 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Procter & Gamble Health Ltd is an India based pharmaceutical company engaged in manufacturing and selling of healthcare products, viz., vitamins, minerals and supplements. Patients are end consumers of the products. The Company's distribution channels (direct & indirect), inter alia, include distributors, health care professionals, pharmacies and chemists. Cosome, Evion, Neurobion, Nasivion, Polybion, Livogen and Seven Seas are some of the brands of the company. The geographical segments include sales in India and exports.
76GF Score
Get the complete analysis for BOM:500126
EBIT per Share is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
BOM:500126 has been successfully added to your 
